ADMA Biologics Total Liab Over Time
| ADMA Stock | USD 21.30 0.07 0.33% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ADMA Biologics Performance and ADMA Biologics Correlation. ADMA |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ADMA Biologics. If investors know ADMA will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ADMA Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 14 | Earnings Share 0.27 | Revenue Per Share 1.661 | Quarterly Revenue Growth 0.781 | Return On Assets 0.1989 |
The market value of ADMA Biologics is measured differently than its book value, which is the value of ADMA that is recorded on the company's balance sheet. Investors also form their own opinion of ADMA Biologics' value that differs from its market value or its book value, called intrinsic value, which is ADMA Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ADMA Biologics' market value can be influenced by many factors that don't directly affect ADMA Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ADMA Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if ADMA Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ADMA Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Total Liab Analysis
Compare ADMA Biologics and related stocks such as Atara Biotherapeutics, Fate Therapeutics, and Sana Biotechnology Total Liab Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ATRA | 8 M | 8 M | 8 M | 62.8 M | 2.9 M | 9.9 M | 10.2 M | 39.9 M | 53 M | 52.2 M | 125.8 M | 188.5 M | 249.8 M | 264.7 M | 278 M |
| FATE | 58.5 M | 58.5 M | 63.9 M | 4.7 M | 22.9 M | 29.9 M | 21.9 M | 28.1 M | 52.6 M | 57.5 M | 238 M | 242.6 M | 221.6 M | 137.8 M | 99.9 M |
| SANA | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 47.5 M | 558.2 M | 1.2 B | 400.9 M | 323.4 M | 277.8 M | 367.9 M |
| CRBU | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 54.5 M | 59.5 M | 54.5 M | 72.9 M | 63.8 M | 67.1 M |
| RCUS | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 36.6 M | 40 M | 39.3 M | 270 M | 750.4 M | 688 M | 633 M | 339.3 M |
| TFFP | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 11 K | 1.8 K | 1.2 M | 1.5 M | 1.3 M | 2 M | 1.2 M | 2.5 M | 1.3 M |
| INMB | 30.8 K | 30.8 K | 30.8 K | 30.8 K | 30.8 K | 30.8 K | 600.8 K | 309.7 K | 823.8 K | 860.5 K | 1.9 M | 19.7 M | 21.7 M | 18.9 M | 19.8 M |
| ANEB | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 241.6 K | 512.5 K | 1.1 M | 260.6 K | 247.6 K |
| ANTX | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 887 K | 24.6 M | 112.7 M | 7.2 M | 14 M | 13.3 M |
| ETNB | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 27.4 M | 5.6 M | 8.1 M | 36.5 M | 45 M | 60 M | 33.5 M |
| MDGL | 29 K | 27.6 M | 28 M | 46.1 M | 35.5 M | 17.8 M | 4.8 M | 10.1 M | 8.4 M | 25.5 M | 47 M | 77.2 M | 165.2 M | 235.2 M | 247 M |
| PLRX | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 3.2 M | 67.4 M | 119.5 M | 12.5 M | 22.2 M | 37.3 M | 38.6 M | 34.4 M |
| ACLX | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 76.3 M | 121.4 M | 250.3 M | 108.9 M | 339.8 M | 197.3 M |
| STOK | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 3.7 M | 2.5 M | 4.3 M | 11.8 M | 21.1 M | 71.2 M | 68.8 M | 72.2 M |
| PLX | 7.3 M | 77.9 M | 82.1 M | 140.3 M | 134.1 M | 86.4 M | 92.2 M | 103.5 M | 114 M | 115.7 M | 95 M | 79.7 M | 66.4 M | 50.9 M | 56.1 M |
| CDTX | 1.6 M | 1.6 M | 1.6 M | 1.6 M | 3.2 M | 6.1 M | 18.8 M | 19.3 M | 20 M | 31.1 M | 49.7 M | 53.8 M | 50.5 M | 75.2 M | 79 M |
| AKBA | 4.9 M | 4.9 M | 4.9 M | 3.9 M | 6.9 M | 11.9 M | 232.1 M | 244.9 M | 360.6 M | 376.4 M | 396.5 M | 449.1 M | 342.5 M | 272.3 M | 247.7 M |
| XFOR | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 43.8 M | 64.2 M | 22.5 M | 14.4 M | 31.5 M | 50.1 M | 52.8 M | 81.5 M | 96.2 M | 55.9 M |
| MCRB | 178 K | 178 K | 178 K | 13.2 M | 144.1 M | 11.5 M | 140 M | 128.8 M | 168.5 M | 180.8 M | 168.2 M | 223.4 M | 338 M | 403.5 M | 423.6 M |
| VXRT | 7.3 M | 39.1 M | 16.1 M | 17.8 M | 27.1 M | 9.9 M | 26.5 M | 21.4 M | 24 M | 24.1 M | 29.2 M | 33.6 M | 43.2 M | 34 M | 44.6 M |
| IBIO | 8.1 M | 3.6 M | 4.3 M | 395 K | 1.3 M | 27.6 M | 27.1 M | 26.9 M | 28.1 M | 37.6 M | 38.4 M | 35.9 M | 25.8 M | 7.4 M | 7 M |
| TNXP | 3 K | 2.9 M | 1.2 M | 2.2 M | 3.5 M | 6.8 M | 2.1 M | 2.1 M | 2.7 M | 5.1 M | 10.5 M | 22.2 M | 18.5 M | 48.9 M | 51.4 M |
| BCRX | 1.6 M | 67.4 M | 57.9 M | 50 M | 61.2 M | 76.8 M | 88.3 M | 94.5 M | 97.6 M | 137 M | 354 M | 695.1 M | 844.6 M | 972.5 M | 1 B |
ADMA Biologics and related stocks such as Atara Biotherapeutics, Fate Therapeutics, and Sana Biotechnology Total Liab description
The total amount of all liabilities that a company has, including both short-term and long-term liabilities.My Equities
My Current Equities and Potential Positions
| ADMA Biologics | ADMA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | New Jersey; U.S.A |
| Exchange | NASDAQ Exchange |
USD 21.3
Check out ADMA Biologics Performance and ADMA Biologics Correlation. For information on how to trade ADMA Stock refer to our How to Trade ADMA Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
ADMA Biologics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.